943319-70-8 | 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	≥98%	in stock	$38.00	$27.00
5mg	95%	in stock	$60.00	$42.00
100mg	95%	in stock	$71.00	$50.00
250mg	98%	in stock	$91.00	$64.00
1g	98%	in stock	$240.00	$168.00
5g	98%	in stock	$840.00	$588.00

Description

• Catalog Number: AB47589
• Chemical Name: 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide
• CAS Number: 943319-70-8
• Molecular Formula: C29H27F3N6O
• Molecular Weight: 532.5595
• MDL Number: MFCD17215203
• SMILES: CN1CCN(CC1)Cc1ccc(cc1C(F)(F)F)NC(=O)c1ccc(c(c1)C#Cc1cnc2n1nccc2)C

Computed Properties

• Complexity: 910
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 39
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 6
• XLogP3: 4.1

Literature

• Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

  Blood 20180726

• Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.

  Toxicology letters 20180701

• Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.

  Toxicology 20180215

• Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.

  Journal of molecular biology 20170217

• A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.

  Nature chemical biology 20151201

• Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.

  Oncotarget 20150821

• PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

  Leukemia 20150501

• A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.

  Toxicological sciences : an official journal of the Society of Toxicology 20150101

• BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.

  Molecular cancer therapeutics 20141001

• Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.

  Molecular and cellular endocrinology 20130905

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.

  Leukemia 20130101

• Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.

  Haematologica 20130101

• Philadelphia-positive acute lymphoblastic leukemia: current treatment options.

  Current oncology reports 20121001

• Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.

  Haematologica 20120901

• The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

  Molecular cancer therapeutics 20120901

• Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.

  Leukemia 20120701

• Clinical trials in chronic myeloid leukemia.

  Current hematologic malignancy reports 20120601

• Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.

  British journal of haematology 20120501

• The ins and outs of bcr-abl inhibition.

  Genes & cancer 20120501

• Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.

  Molecular cancer therapeutics 20120301

• The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm.

  Cancer 20120115

• An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents.

  Methods in molecular biology (Clifton, N.J.) 20120101

• The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

  Blood 20111110

• [Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?].

  Bulletin du cancer 20110701

• Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.

  Bioorganic & medicinal chemistry letters 20110615

• New drugs for chronic myelogenous leukemia.

  Current hematologic malignancy reports 20110601

• Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.

  Molecular cancer therapeutics 20110601

• Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood.

  Korean journal of pediatrics 20110301

• Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110115

• Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.

  Chemical biology & drug design 20110101

• Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

  Journal of medicinal chemistry 20100624

• AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

  Cancer cell 20091106

• Inhibitors of ABL and the ABL-T315I mutation.

  Current topics in medicinal chemistry 20080101